Literature DB >> 14769369

Transient ischemia of the retina results in massive degeneration of the retinotectal projection: long-term neuroprotection with brimonidine.

Marcelino Avilés-Trigueros1, Sergio Mayor-Torroglosa, Antonio García-Avilés, María P Lafuente, María E Rodríguez, Jaime Miralles de Imperial, María P Villegas-Pérez, Manuel Vidal-Sanz.   

Abstract

In adult rats, we have induced retinal ischemia and investigated anterogradely labeled surviving retinal ganglion cell (RGC) afferents to the contralateral superior colliculus (SC). The animals received topically in their left eyes two 5-microl drops of saline or saline-containing 0.5% brimonidine (BMD), 1 h before 90 min of retinal ischemia induced by ligature of the left ophthalmic vessels. Two months after ischemia, the anterogradely transported neuronal tracer cholera toxin B subunit (CTB) was injected in the ischemic eyes and animals were processed 4 days later. As controls and for comparison, the retinotectal innervation of unlesioned age-matched control rats was also examined with CTB. In control and experimental animals, serial coronal sections of the mesencephalon and brainstem were immunoreacted for CTB and the area and thickness of the two most superficial layers of the SC containing densely CTB-labeled profiles were estimated with an image analysis system. Ninety minutes of ischemia resulted 2 months later in reduced density of CTB-labeled profiles in the contralateral SC of the vehicle-treated rats, representing less than one half the area occupied by CTB-labeled profiles in control rats. This resulted in shrinkage of these layers and in the presence of areas virtually devoid of CTB immunoreactivity, suggesting orthograde degeneration of retinal terminals and/or decrease of anterograde axonal transport. Topical pretreatment with BMD resulted 2 months later in CTB immunoreactivity that occupied the superficial layers of the contralateral SC in an area of approximately 86% of that observed in the unlesioned control group of animals, indicating that BMD protects against ischemia-induced degeneration of the retinotectal projection, and preserves anterograde axonal transport.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14769369     DOI: 10.1016/S0014-4886(03)00298-X

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  21 in total

Review 1.  Topical drug therapy in glaucoma.

Authors:  Hemma Resch; Gerhard Garhofer
Journal:  Wien Med Wochenschr       Date:  2006-09

Review 2.  Inducible rodent models of glaucoma.

Authors:  Iok-Hou Pang; Abbot F Clark
Journal:  Prog Retin Eye Res       Date:  2019-09-23       Impact factor: 21.198

Review 3.  Pharmacological neuroprotection for glaucoma.

Authors:  Glyn Chidlow; John P M Wood; Robert J Casson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Distal axonopathy with structural persistence in glaucomatous neurodegeneration.

Authors:  Samuel D Crish; Rebecca M Sappington; Denise M Inman; Philip J Horner; David J Calkins
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

5.  Brimonidine protects against loss of Thy-1 promoter activation following optic nerve crush.

Authors:  Yi Dai; James D Lindsey; Karen X Duong-Polk; Panida Chindasub; Christopher Kai-Shun Leung; Robert N Weinreb
Journal:  BMC Ophthalmol       Date:  2013-06-27       Impact factor: 2.209

6.  Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons.

Authors:  Wendi S Lambert; Lupe Ruiz; Samuel D Crish; Larry A Wheeler; David J Calkins
Journal:  Mol Neurodegener       Date:  2011-01-13       Impact factor: 14.195

7.  Effects of ocular hypertension in the visual system of pigmented mice.

Authors:  Francisco J Valiente-Soriano; Manuel Salinas-Navarro; Manuel Jiménez-López; Luis Alarcón-Martínez; Arturo Ortín-Martínez; José M Bernal-Garro; Marcelino Avilés-Trigueros; Marta Agudo-Barriuso; María P Villegas-Pérez; Manuel Vidal-Sanz
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

8.  Axonal protection by brimonidine with modulation of p62 expression in TNF-induced optic nerve degeneration.

Authors:  Yasushi Kitaoka; Kaori Kojima; Yasunari Munemasa; Kana Sase; Hitoshi Takagi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-12       Impact factor: 3.117

9.  Short and long term axotomy-induced ERG changes in albino and pigmented rats.

Authors:  Luis Alarcón-Martínez; Pedro de la Villa; Marcelino Avilés-Trigueros; Román Blanco; Maria P Villegas-Pérez; Manuel Vidal-Sanz
Journal:  Mol Vis       Date:  2009-11-17       Impact factor: 2.367

10.  Agmatine protects retinal ganglion cells from hypoxia-induced apoptosis in transformed rat retinal ganglion cell line.

Authors:  Samin Hong; Jong Eun Lee; Chan Yun Kim; Gong Je Seong
Journal:  BMC Neurosci       Date:  2007-10-02       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.